Methods comprising apoptosis inhibitors for the generation of transgenic pigs |
 |
|
|
||||||||||||||||||||||||||||||||||||||||||
| Title: | Hematopoietic facilitatory cells and their uses |
| Inventors: | Ildstad, Suzanne T.; Pittsburgh, PA, USA Simmons, Richard L.; Pittsburgh, PA, USA Ricordi, Camillo; Miami Beach, FL, USA Wren, Sherry M.; Pittsburgh, PA, USA Kaufman, Christina; Munhall, PA, USA |
| Summary: | Described herein are pure mammalian hematopoietic facilitatory cells (FC), methods and uses thereof. The invention relates to the capacity of such FC to facilitate the engraftment of bone marrow cells without producing graft-versus-host disease. Further disclosed are methods of isolation and characterization of the FC, which are distinguishable from all other known bone marrow cells by their morphology, cell surface phenotype and in vivo function. Central to the invention is the discovery that purified hematopoietic stem cells alone or bone marrow cells depleted of FC do not readily engraft in a recipient, but when co-administered with other bone marrow cells, especially hematopoietic stem cells, into a recipient, the FC have been shown to enhance engraftment. Further claims of the invention include the ability of the FC to enhance the engraftment of bone marrow cells in establishing lymphohematopoietic chimerism without producing graft-versus-host disease. Therapeutic applications are included for the facilitation of solid organ, tissue and cellular transplantation, and for hematopoietic reconstitution by bone marrow transplantation for the treatment of cancer, anemia, autoimmune and immunodeficiency disorders, viral infections and metabolic disorders. |
| Abstract: | The present invention relates to mammalian hematopoietic facilitatory cells (FC). In particular, it relates to the isolation, characterization and uses of the FC. The FC of the present invention can be distinguished from all other known bone marrow cells by their morphology, cell surface phenotype and in vivo function. It has now been established that purified hematopoietic stem cells alone or bone marrow cells depleted of FC do not readily engraft in a recipient. When co-administered with other bone marrow cells, especially the hematopoietic stem cells into a recipient, the FC enhance their engraftment, without apparent adverse biologic activities. In fact, the ability of the FC to enhance the engraftment of bone marrow cells in esablishing lymphohematopoietic chimerism without producing graft versus host disease also induces donor-specific tolerance to permit the permanent acceptance of donor's cells, tissues and organs. Therefore, FC may have a wide range of applications, including, but not limited to, hematopoietic reconstitution by bone marrow transplantation for the treatment of cancers, anemias, autoimmunity, immunodeficiency, viral infections and metabolic disorders as well as facilitation of solid organ, tissue and cellular transplantation. |
| US Patent Website: | Click Here for Full Text of Patent |
| Title Number: | US5772994 |
| Application Number: | US1995000463908 |
| Date Filed: | 05/06/1995 |
| Date Published: | 30/06/1998 |
| Assignee: | The University of Pittsburgh, Pittsburgh, PA, USA |